Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


Shares of nano-cap company AnPac Bio-Medical Science Co., Ltd. (ANPC) are gaining over 16% on Monday morning after the biotech company announced that its investee company in China received COVID-19 nucleic acid test certification.


RTTNews | Nov 2, 2020 10:16AM EST

10:16 Monday, November 2, 2020 (RTTNews.com) - Shares of nano-cap company AnPac Bio-Medical Science Co., Ltd. (ANPC) are gaining over 16% on Monday morning after the biotech company announced that its investee company in China received COVID-19 nucleic acid test certification.

ANPC is currently trading at $3.73, up $0.52 or 16.1994%, on the Nasdaq.

AnPac Bio-Medical Science, a biotechnology company with operations in China and the US, said that its investee company in China, Jiangsu AnPac Health Management Co., Ltd., qualified for COVID-19 nucleic acid tests in the first half of 2020 and received certification from the regulatory authority on October 17, 2020 for COVID-19 nucleic acid tests.

Recently, AnPac Bio and Jiangsu AnPac have signed an agreement to develop and qualify new COVID-19 test technologies and products, and carry out evaluations at Jiangsu AnPac's medical lab.

Read the original article on RTTNews ( https://www.rttnews.com/3142019/stock-alert-anpac-bio-medical-science-up-16.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC